403 related articles for article (PubMed ID: 32469301)
1. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.
Pokhrel R; Chapagain P; Siltberg-Liberles J
J Med Microbiol; 2020 Jun; 69(6):864-873. PubMed ID: 32469301
[No Abstract] [Full Text] [Related]
2. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
[TBL] [Abstract][Full Text] [Related]
3. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
F1000Res; 2020; 9():1166. PubMed ID: 33204411
[No Abstract] [Full Text] [Related]
4. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
[TBL] [Abstract][Full Text] [Related]
5. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
[TBL] [Abstract][Full Text] [Related]
6. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.
Khan A; Khan M; Saleem S; Babar Z; Ali A; Khan AA; Sardar Z; Hamayun F; Ali SS; Wei DQ
Interdiscip Sci; 2020 Sep; 12(3):335-348. PubMed ID: 32617855
[TBL] [Abstract][Full Text] [Related]
7. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
9. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.
Aftab SO; Ghouri MZ; Masood MU; Haider Z; Khan Z; Ahmad A; Munawar N
J Transl Med; 2020 Jul; 18(1):275. PubMed ID: 32635935
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide analogues as inhibitors of SARS-CoV Polymerase.
Ju J; Li X; Kumar S; Jockusch S; Chien M; Tao C; Morozova I; Kalachikov S; Kirchdoerfer RN; Russo JJ
Pharmacol Res Perspect; 2020 Dec; 8(6):e00674. PubMed ID: 33124786
[TBL] [Abstract][Full Text] [Related]
11. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B
Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108
[TBL] [Abstract][Full Text] [Related]
12. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
13. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Elfiky AA
Life Sci; 2020 May; 248():117477. PubMed ID: 32119961
[TBL] [Abstract][Full Text] [Related]
14. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628
[TBL] [Abstract][Full Text] [Related]
15. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
Elfiky AA
Life Sci; 2020 Jul; 253():117592. PubMed ID: 32222463
[TBL] [Abstract][Full Text] [Related]
16. Alkaloids from
Borquaye LS; Gasu EN; Ampomah GB; Kyei LK; Amarh MA; Mensah CN; Nartey D; Commodore M; Adomako AK; Acheampong P; Mensah JO; Mormor DB; Aboagye CI
Biomed Res Int; 2020; 2020():5324560. PubMed ID: 33029513
[TBL] [Abstract][Full Text] [Related]
17. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
Jockusch S; Tao C; Li X; Anderson TK; Chien M; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
Antiviral Res; 2020 Aug; 180():104857. PubMed ID: 32562705
[TBL] [Abstract][Full Text] [Related]
18. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
Chien M; Anderson TK; Jockusch S; Tao C; Li X; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
J Proteome Res; 2020 Nov; 19(11):4690-4697. PubMed ID: 32692185
[TBL] [Abstract][Full Text] [Related]
20. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
